Verastem Inc. Common Stock (VSTM)
Stock · NASDAQ · Health Care
$8.65as of 10/16/2026
Price chart
Active signals
VSTM Signal Track Record
How signals performed across all stocks →What VSTM's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume SpikeActive now | 44 | -4.6% | 43% | September 18, 2026 |
| Bollinger Band Breakout | 26 | -5.6% | 42% | September 22, 2026 |
| Bollinger Band Breakdown | 19 | -2.6% | 47% | June 25, 2026 |
| 200-Day Moving Average TouchActive now | 8 | +21.4% | 63% | December 30, 2025 |
| Any 20-session window (baseline) | +0.9% | 51% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About VSTM
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway t…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 102
- Website
- www.verastem.com/
Fundamentals
- 1-day range
- $8.53$9.37
- Market cap
- $519.33M
- P/E (trailing)
- —
- P/E (forward)
- -7.09
- EPS (trailing)
- $-2.46
- Dividend yield
- —
- Beta
- 0.59
- Avg. volume
- 3.00M
How Verastem Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 4, 2026 · via SEC EDGAR / Finnhub
Forecasts
9 analyst ratings
Verastem Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- VSTMVerastem Inc. Common Stock$8.65▼ 6.28%Market cap $519.33MP/E —$3.43$10.82
- BIOABioAge Labs Inc. Common Stock$4.84▼ 9.53%Market cap $500.98MP/E —$5.04$25.96
- SGMTSagimet Biosciences Inc. Series A Common Stock$8.02▼ 1.84%Market cap $539.71MP/E —$4.5$11.45
- TENXTenax Therapeutics Inc. Common Stock$1.36▼ 9.93%Market cap $498.11MP/E —$1.31$19.4
- OVIDOvid Therapeutics Inc. Common Stock$2.15▼ 4.87%Market cap $494.60MP/E —$1.18$3.11
- AQSTAquestive Therapeutics Inc. Common Stock$3.78▼ 6.90%Market cap $491.83MP/E —$2.93$7.55
- SLNSilence Therapeutics Plc American Depository Share$8.68▼ 7.17%Market cap $548.50MP/E —$1.06$5.99
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| VSTM Verastem Inc. Common Stock | $519.33M | — | $8.65 | ▼ 6.28% | $3.43$10.82 |
| BIOA BioAge Labs Inc. Common Stock | $500.98M | — | $4.84 | ▼ 9.53% | $5.04$25.96 |
| SGMT Sagimet Biosciences Inc. Series A Common Stock | $539.71M | — | $8.02 | ▼ 1.84% | $4.5$11.45 |
| TENX Tenax Therapeutics Inc. Common Stock | $498.11M | — | $1.36 | ▼ 9.93% | $1.31$19.4 |
| OVID Ovid Therapeutics Inc. Common Stock | $494.60M | — | $2.15 | ▼ 4.87% | $1.18$3.11 |
| AQST Aquestive Therapeutics Inc. Common Stock | $491.83M | — | $3.78 | ▼ 6.90% | $2.93$7.55 |
| SLN Silence Therapeutics Plc American Depository Share | $548.50M | — | $8.68 | ▼ 7.17% | $1.06$5.99 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026Yahoo · 10/2/2026
- Verastem Oncology To Present Data From New Molecular Profiling, Tumor Biomarker Analysis Of Phase 2 RAMP 201 Clinical Trial Of Avutometinib Plus Defactinib In Patients With Recurrent LGSOC, At IGCS 2026Benzinga · 10/2/2026
- Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian CancerYahoo · 9/28/2026
- KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034Yahoo · 9/28/2026
- Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global MeetingYahoo · 9/24/2026
- Verastem Highlights Ovarian Cancer Launch, KRAS G12D Program at H.C. WainwrightYahoo · 9/22/2026
- Wolfe Research Initiates Coverage On Verastem with Outperform RatingBenzinga · 9/17/2026
- HC Wainwright & Co. Reiterates Buy on Verastem, Maintains $18 Price TargetBenzinga · 9/11/2026
Insider Activity
Insider Actions →- Dan Paterson · October 1, 2026 · Sale44.1K @ $8
- Daniel Calkins · October 1, 2026 · Sale2.6K @ $8
- Dan Paterson · September 30, 2026 · Grant106.9K
- Daniel Calkins · September 30, 2026 · Grant8.3K
- Daniel Calkins · September 21, 2026 · Sale55 @ $7.7
- Dan Paterson · August 3, 2026 · Sale1.3K @ $5.81
- Dan Paterson · June 22, 2026 · Sale20.9K @ $4.18
- Daniel Calkins · June 22, 2026 · Sale57 @ $4.13
- Daniel Calkins · June 22, 2026 · Sale4.0K @ $4.18
- Michelle Robertson · May 21, 2026 · Grant36.0K
- Anil Kapur · May 21, 2026 · Grant36.0K
- Paul A. Bunn · May 21, 2026 · Grant36.0K
- John Johnson · May 21, 2026 · Grant36.0K
- Eric K. Rowinsky · May 21, 2026 · Grant36.0K
- Michael P. Bailey · May 21, 2026 · Grant108.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 80.62M
- Total value held
- $424.35M
- Institutional holders
- 151
- Unknown6.58M
- Unknown6.19M
- Unknown5.74M
- Unknown4.59M
- Unknown3.58M
- Unknown3.52M
- Unknown3.32M
- Unknown3.30M
- Unknown3.15M
- Unknown2.41M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Verastem presents ovarian cancer data at IGCS, outlines pipeline
Verastem Oncology reported a late‑breaking oral presentation of its RAMP 201 low‑grade serous ovarian cancer molecular profiling and tumor biomarker analysis at the IGCS 2026 Annual Global Meeting. The company also highlighted the launch of its ovarian cancer therapy and progress on the KRAS G12D program during an H.C. Wainwright event. These updates reflect ongoing clinical development and investor communication around its oncology pipeline.
Verastem presents ovarian cancer data at IGCS, outlines pipeline. Verastem Oncology reported a late‑breaking oral presentation of its RAMP 201 low‑grade serous ovarian cancer molecular profiling and tumor biomarker analysis at the IGCS 2026 Annual Global Meeting. The company also highlighted the launch of its ovarian cancer therapy and progress on the KRAS G12D program during an H.C. Wainwright event. These updates reflect ongoing clinical development and investor communication around its oncology pipeline.